Top

Published in:

01-08-2007 | Original Paper

Results of an Intervention for Individuals and Families with BRCA Mutations: A Model for Providing Medical Updates and Psychosocial Support Following Genetic Testing

Authors: Wendy McKinnon, Shelly Naud, Taka Ashikaga, Rose Colletti, Marie Wood

Published in: Journal of Genetic Counseling | Issue 4/2007

Abstract

Providing medical management updates and long-term support to families with hereditary cancer syndromes in rural areas is a challenge. To address this, we designed a one-day retreat for BRCA1/2 carriers in our region. The retreat included educational updates about medical management, genetic privacy and discrimination, and addressed psychological and family issues. Evaluations completed at the conclusion of the retreat were overwhelmingly positive with requests for a similar event in the future. The impact of this retreat on a variety of health behaviors was assessed. Eligible participants completed questionnaires before and 6 months after the retreat. Questionnaires focused on lifestyle, cancer screening and prevention practices, psychological history and distress, decision-making regarding genetic testing, and family communication issues. For individuals who completed both the pre and post retreat questionnaires, one-half made lifestyle changes and nearly two-thirds increased cancer screening, initiated chemoprevention, completed or planned to complete preventative surgery in the future. We conclude that this type of forum provides a valuable opportunity for BRCA carriers and their families to receive updated medical information, share personal experiences, provide and receive support, as well as change health behaviors.

Antoniou, A., Pharoah, P. D., Narod, S., Risch, H. A., Eyfjord, J. E., Hopper, J. L., et al. (2003). Average risks of breast and ovarian cancer associated with BRCA1 and BRCA2 mutations detected in case series unselected for family history: A combined analysis of 22 studies. Am J Hum Genet, 72, 1117–1130.CrossRef

Armstrong, K., Calzone, K., Stopfer, J., Fitzgerald, G., Coyne, J., & Weber, B. (2000). Factors associated with decisions about clinical BRCA1/2 testing. Cancer, Epidem, Bio Prev, 9, 1251–1254.

Breast Cancer Linkage Consortium. (1999). Cancer risks in BRCA2 mutation carriers. J Natl Cancer Inst, 91, 1310–1316.CrossRef

Cella, D. F., Mahon, S. M., & Donovan, M. I. (1990). Cancer recurrence as a traumatic event. Behav Med, 16, 15022.CrossRef

d’Agincourt-Canning, L. (2001). Experience of genetic risk: Disclosure and the gendering of responsibility. Bioethics, 15(3), 231–247.CrossRef

Di Prospero, L. S., Seminsky, M., Honeyford, J., Doan, B., Franssen, E., Mechino, W., Chart, P., & Warner, E. (2001). Psychosocial issues following a positive result of genetic testing for BRCA1 and BRCA2 mutations: findings from a focus group and a needs-assessment survey. CMAJ, 164(7), 1005–1009.PubMedPubMedCentral

Dorval, M., Maunsell, E., Dugas, M. J., & Simard, J. (2001). Support groups for people carrying a BRCA mutation. JAMC, 165(6), 740.

Dunkel-Schetter, C. (1984). Social support and cancer: findings based on patient interviews and their interpretations. J Soc Issues, 40, 77–98.CrossRef

Easton, D. F., Ford, D., & Bishop, D. T. (1995). Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Am J Hum Genet, 56, 265–271.CrossRef

Esplen, M. J., Hunter, J., Leszcz, M., Warner, E., Narod, S., Metcalfe, K., et al. (2004). A multicenter study of supportive-expressive group therapy for women with BRCA1/BRCA2 mutations. Cancer, 101, 2327–2340.CrossRef

Ford, D., Easton, D. F., Bishop, D. T., Narod, S.A., & Goldgar, D. E. (1994). Risks of cancer in BRCA1-mutation carriers. Lancet, 343, 692–695.CrossRef

Forrest, K., Simpson, S. A., Wilson, B. J., van Teijlingen, E. R., McKee, L., Haites, N., & Matthews, E. (2003). To tell or not to tell: barriers and facilitators in family communication about genetic risk. Clin Genet, 64, 317–326.CrossRef

Friedenson, B. (2005). BRCA1 and BRCA2 pathways and the risk of cancers other than breast or ovarian. Medscape Gen Med, 7(2), 60.

Galinsky, M. J., & Schopler, J. H. (1994). Negative experiences in support groups. Social Work Health Care Special Issue, 20, 77–95.CrossRef

Gray, R. E., James, P., Manthorne, B. A., Gould, J., & Fitch, M. I. (2004). A consultation with Canadian rural women with breast cancer. Health Exp, 7, 40–50.CrossRef

Hallowell, N., & Murton, F. (1998). The value of written summaries of genetic consultations. Patient Edu Couns, 35(1), 27–34.CrossRef

Horowitz, M., Wilner, N., & Alvarez, W. (1979). Impact of event scale: A measure of subjective stress. Psychosom Med, 41, 209–218.CrossRef

Horowitz, M. (1982). Stress response syndromes and their treatment. In: Goldberg, L., and Breznitz, S. (Eds.), Handbook of stress: Theoretical and clinical aspects. Free Press: New York, pp. 711–732.

Hughes, C., Lerman, C., Schwartz, M., Peshkin, B., Wenzel, L., Narod, S., Corio, C., Tercyak, K., Hanna, D., Isaacs, C., & Main, D. (2002). All in the family: Evaluation of the process and content of sisters’ communication about BRCA1 and BRCA2 genetic test results. Am J Med Genet, 107, 143–150.CrossRef

Karp, J., Brown, K. L., Sullivan, M. D., & Massie, M. J. (1999). The prophylactic mastectomy dilemma: A support group for women at high genetic risk for breast cancer. J Genet Couns, 8(3), 163–173.CrossRef

Kelly, K., Leventhal, H., Andrykowksi, M., Toppmeyer, D., Much, J., Dermody, J., Marvin, M., Baran, J., & Schwalb, M. (2004). The decision to test in women receiving genetic counseling for BRCA1 and BRCA2 mutations. J Genet Couns, 13(3), 237–257.CrossRef

King, M. C., Marks, J. H., & Handell, J.B. (2003). Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science, 302, 643.CrossRef

Kotsopoulos, J., & Narod, S. A. (2005). Towards a dietary prevention of hereditary breast cancer. Can Causes Contr, 16, 125–138.CrossRef

Lerman, C., Biesecker, B. B., Benkendorf, J. L., Kerner, J., Gomez-Caminero, A., Hughes, C., et al. (1997). Controlled trial of pretenst education approaches to enhance infored decision-making for BRCA1 gene testing. J Natl Cancer Inst, 89(2), 148–157.CrossRef

Lerman, C., Hughes, C., Lemon, S. J., Lemon, S. J., Main, D., Snyder, C., et al. (1998). What you don't know can hurt you: Adverse psychologic effects in members of BRCA1-linked and BRCA2-linked families who decline genetic testing. J Clin Oncol, 16, 1639–1641.CrossRef

Liede, A., Karlan, B. Y., & Narod, S. A. (2004). Cancer risks for male carriers of germline mutations in BRCA1 or BRCA2: A review of the literature. J Clin Oncol, 22, 735–742.CrossRef

Liede, A., Metcalfe, K., Hanna, D., Hoodfar, E., Snyder, C., Durham, C., et al. (2000). Evaluation of the needs of male carries of mutations in BRCA1 or BRCA2 who have undergone genetic counseling. Am J Hum Genet, 67, 1494–1504.CrossRef

Lodder, L., Frets, P. G., Trijsburg, R. W., Klijn, J. G., Seynaeve, C., Tilanus, M. M., et al. (2003). Attitudes and distress levels in women at risk to carry a BRCA1/BRCA2 gene mutation who decline genetic testing. Am J Med Genet, 119A, 266–272.CrossRef

Lynch, H. T., Watson, P., Tinley, S., Snyder, C., Durham, C., Lynch, J., et al. (1999). An update on DNA-based BRCA1/BRCA2 genetic counseling in hereditary breast cancer. Can Genet Cytogenet, 109, 91–98.CrossRef

McInerney-Leo, A., Biesecker, B. B., Hadley, D. W., Kase, R. G., Giambarresi, T. R., Johnson, E., Lerman, C., & Struewing, J. P. (2005). BRCA1/2 testing in hereditary breast and ovarian cancer families II: Impact on relationships. Am J Med Genet, 133A, 165–169.CrossRef

McKinnon, W., Guttmacher, A., Greenblatt, M., Compas, B., May, S., Cutler, R., & Yandell, D. (1997). The familial cancer program of the vermont cancer center: Development of a cancer genetics program in a rural area. J Genet Coun, 6(2), 131–145.CrossRef

Meiser, B. (2005). Psychological impact of genetic testing for cancer susceptibility: An update of the literature. Psycho-Oncology, 14, 1060–1074.CrossRef

Metcalfe, K. A., Liede, A., Trinkaus, M., Hanna, D., & Narod, S. A. (2002). Evaluation of the needs of spouses of female carriers of mutations in BRCA1 and BRCA2. Clin Genet, 62, 464–469.CrossRef

Metcalf, K., Lynch, H. T., Ghadirian, P., Tung, N., Olivotto, I., Warner, E., et al. (2004). Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. J Clin Oncol, 22, 2328–2335.CrossRef

Miki, Y., Swensen, J., Shattuck-Eidens, D., Futreal, P. A., Harshman, K., Tavtigian, S., et al. (1994). A strong candidate for the breast cancer and ovarian cancer susceptibility gene BRCA1. Science, 226, 66–71.CrossRef

Montazeri, A., Jarvandi, S., Haghighat, S., Vahdani, M., Sajadian, A., Ebrahimi, M., & Haji-Mahmoodi, M. (2001). Anxiety and depression in breast cancer patients before and after participation in a cancer support group. Patient Educ Couns, 45, 195–198.CrossRef

Narod, S. A., & Offit, K. (2005). Prevention and management of hereditary breast cancer. J Clin Oncol, 23, 1656–1663.CrossRef

Peterson, S. K., Watts, B. G., Koehly, L. M., Vernon, S. W., Baile, W. F., Kohlman, W. K., & Gritz, E. R. (2003). How families communicate about HNPCC testing: Findings from a qualitative study. Am J Med Genet, 119C, 78–86.CrossRef

Speice, J., McDonald, S. H., Rowley, P. T., & Loader, S. (2002). Family issues in a psychoeducation group for women with a BRCA mutation. Clin Genet, 62, 121–127.CrossRef

Thewes, B., Meiser, B., & Hickie, I. (2001). Psychometric properties of the impact of event scale amongst women at increased risk for hereditary breast cancer. Psycho-Oncology, 10, 459–468.CrossRef

Von Riper, M., & McKinnon, W. (2004). Genetic testing for breast and ovarian cancer susceptibility: A family experience. J Midwifery Womens Health, 49, 210–219.CrossRef

Wainberg, S., & Husted, J. (2004). Utilization of screening and preventive surgery among unaffected carriers of a BRCA1 or BRCA2 gene mutation. Can Epidemiol Biomarkers Prev, 13(12), 1989–1995.

Wideroff, L., Vadaparampil, S. T., Greene, M. H., Talin, S., Olson, L., & Freedman, A. N. (2005). Hereditary breast/ovarian and colorectal cancer genetics knowledge in a national sample of US physicians. J Med Genet, 42, 749–755.CrossRef

Wooster, R., Bignell, G., Lancaster, J., Swift, S., Seal, S., Mangion, J., et al. (1995). Identification of the breast cancer susceptibility gene BRCA2. Nature, 378, 789–792.CrossRef

Title: Results of an Intervention for Individuals and Families with BRCA Mutations: A Model for Providing Medical Updates and Psychosocial Support Following Genetic Testing
Authors: Wendy McKinnon
Shelly Naud
Taka Ashikaga
Rose Colletti
Marie Wood
Publication date: 01-08-2007
Publisher: Springer US
Published in: Journal of Genetic Counseling / Issue 4/2007
Print ISSN: 1059-7700
Electronic ISSN: 1573-3599
DOI: https://doi.org/10.1007/s10897-006-9078-8

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Results of an Intervention for Individuals and Families with BRCA Mutations: A Model for Providing Medical Updates and Psychosocial Support Following Genetic Testing

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2007

Successful Use of Peer Educators for Sharing Genetic Information

Parents’ Perceptions of Functioning in Families Having a Child with a Genetic Condition

Disclosure of Genetics Research Results after the Death of the Patient Participant: A Qualitative Study of the Impact on Relatives

Knowledge and Attitudes Towards Genetic Testing: A Two Year Follow-Up Study in Patients with Asthma, Diabetes Mellitus and Cardiovascular Disease

What do Patients Prefer: Informed Consent Models for Genetic Carrier Testing

Psychological Follow-up of Presymptomatic Genetic Testing for Spinocerebellar Ataxia Type 2 (SCA2) in Cuba